A Phase II Study of DMP 115 to Assess Focal Liver Lesions

Lantheus Medical Imaging

Status and phase: Completed; Phase 2

Conditions: Liver Disease

Treatments: Drug: Peflutren Lipid Microsphere Injectable Suspension

Study type: Interventional

Funder types: Industry

Identifiers

NCT00162058

DMP 115-214

Details and patient eligibility

About

To determine the optimal dose of DMP 115 to image liver lesions and to assess whether contrast can improve the detection of focal liver lesions.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with 1 but <7 focal liver lesions
• Scheduled for liver biopsy within 30 days of study
• Scheduled for CT or MR within 30 days of study

Exclusion criteria

• Critically ill subjects
• Subjects with right-to-left shunts